Related Experiment Videos
Darifenacin: Pharmacology and clinical usage
1Department of Urology, University of Virginia School of Medicine, University of Virginia Health System, Box 800422 Hospital Drive, Charlottesville, VA 22908, USA. wds6t@virginia.edu
Abstract:
Darifenacin is one of several recently approved antimuscarinics for the treatment of overactive bladder (OAB) and urge urinary incontinence. Darifenacin is an effective drug for the treatment of OAB and is tolerated by patients. Darifenacin's M3 selectivity is unique among antimuscarinics. This M3 selectivity could confer advantages in patients who have cardiovascular side effects (tachycardia), impaired cognition, complaints of dizziness, or sleep disturbances. In some studies, darifenacin caused less dry mouth than oxybutynin. Rates of constipation, although significant, are tolerated and rarely a cause for discontinuation in clinical trials. This review describes the role of M3 receptors and covers the mechanism of action, pharmacokinetic properties, clinical efficacy safety and tolerability, drug interactions, and dosing guidelines for darifenacin.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions